---
layout: full_article
title: "P-Glycoprotein Expression on Patients with Acute Lymphoblastic Leukemia"
author: "R. Niiruri, I. Narayani, K. Ariawati, S. Herawati"
categories: jhsm
canonical_url: https://jurnal.harianregional.com/jhsm/full-34823 
citation_abstract_html_url: "https://jurnal.harianregional.com/jhsm/id-34823"
citation_pdf_url: "https://jurnal.harianregional.com/jhsm/full-34823"  
comments: true
---

<p><span class="font2">&gt; Journal of Health Sciences and Medicine UNUD Journals, Vol. 1 No. 1, February 2017</span></p>
<p><span class="font2">39</span></p><a name="caption1"></a>
<h1><a name="bookmark0"></a><span class="font4"><a name="bookmark1"></a>P-Glycoprotein Expression on Patients with Acute Lymphoblastic Leukemia</span></h1>
<p><span class="font3">R. Niruri<sup>1</sup>, I. Narayani<sup>2</sup>, K. Ariawati<sup>3</sup>, and S. Herawati<sup>4</sup></span></p>
<ul style="list-style:none;"><li>
<p><span class="font2"><sup>1</sup>Department of Pharmacy, Faculty of Mathematic and Sciences, Udayana University</span></p></li></ul>
<p><span class="font2">Bali-Indonesia</span></p>
<p><span class="font2">E-mail : </span><a href="mailto:rasmaya@yahoo.com"><span class="font2">rasmaya@yahoo.com</span></a></p>
<ul style="list-style:none;"><li>
<p><span class="font2"><sup>2</sup> Department of Biology, Faculty of Mathematic and Sciences, Udayana University, Bali-Indonesia</span></p></li>
<li>
<p><span class="font2"><sup>3</sup>Divison of Hematology Oncology, Department of Pediatrician, Sanglah Hospital,</span></p></li></ul>
<p><span class="font2">Bali-Indonesia</span></p>
<ul style="list-style:none;"><li>
<p><span class="font2"><sup>4</sup>Department of Clinical Pathology, Faculty of Medicine, Udayana University,</span></p></li></ul>
<p><span class="font2">Bali-Indonesia</span></p>
<p><span class="font2" style="font-weight:bold;">Abstract</span></p>
<p><span class="font2">Objective: P-glycoprotein (P-gp) overexpression on neoplastic cells can deteriorate the therapeutic outcome on cancer patients. P-gp plays important role on drug efficacy and toxicity. This research aimed to measure P-gp expression on children with Acute Lymphoblastic Leukemia (ALL) on Sanglah Hospital, Denpasar. Method: Flowcytometry method was used to measure P-gp expression level on Bone Marrow samples from pediatric patients (0-12 years old) who were newly diagnosed with ALL in Sanglah Hospital. P-gp overexpression were based on the percentage of cell stained. Ten percent of P-gp expression were considered as the cut-off value of P-gp overexpression. Result: On this study, 11 samples were obtained with the range value of 56-97% on P-gp expression. Conclusion: All 11 patients had P-gp overexpression.</span></p>
<p><span class="font1" style="font-weight:bold;font-style:italic;">Keywords :</span><span class="font2" style="font-weight:bold;"> ALL children, BMA, P-gp</span></p>
<ul style="list-style:none;"><li>
<h2><a name="bookmark2"></a><span class="font2"><a name="bookmark3"></a>I.</span><span class="font2" style="font-variant:small-caps;"> &nbsp;&nbsp;&nbsp;Introduction<sup>9</sup></span></h2></li></ul>
<p><span class="font2">P-glycoprotein (P-gp) overexpression can decrease intracellular drug concentration, such as vinblastine, vincristine, and daunomycin. P-gp may overexpressed on neoplastic cells. It can deteriorate the therapeutic response and prognosis on cancer therapy, such as on Acute Myeoblastic Leukemia (AML). P-gp plays important role in drug efficacy and toxicity [1], [2].</span></p>
<p><span class="font2">On leukemia, </span><span class="font2" style="font-style:italic;">myeloma, lymphoma</span><span class="font2">, and solid tumor (such as breast and ovarium cancer), the detection of drug resistances marker can help to choose drugs therapy. Low expression of P-gp can be a prediction marker on therapeutic result, such as in ovarium cancer [3], [4].</span></p>
<p><span class="font2">This study was aimed to evaluate P-gp expression on children with ALL in Sanglah Hospital, Bali.</span></p>
<ul style="list-style:none;"><li>
<h2><a name="bookmark4"></a><span class="font2"><a name="bookmark5"></a>II.</span><span class="font2" style="font-variant:small-caps;"> &nbsp;&nbsp;&nbsp;Methods and procedures</span></h2></li></ul>
<p><span class="font2">This laboratory exploration study was approved by Ethical committee of Sanglah Hospital – Faculty of Medicine Udayana University.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font2" style="font-style:italic;">K. &nbsp;&nbsp;&nbsp;Samples</span></p></li></ul>
<p><span class="font2">Bone marrow aspirates (BMA) (1 ml) were collected in ethylenediamine tetraacetic acid (EDTA) tubes from subjects (newly diagnosed children (0-12 years old) with ALL, who did not receive chemotherapy yet and signed inform consent) on the period of June 2015 – January 2016. The samples were sent to Clinical Pathology Laboratory, Dr Sutomo Hospital-Faculty of Medicine Airlangga University, Surabaya. P-gp Expression were measured in the period of 24 hours after the samples were drawn.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font2" style="font-style:italic;">L. &nbsp;&nbsp;&nbsp;P-gp expression</span></p></li></ul>
<p><span class="font2" style="font-style:italic;">BD reagent anti P-gp PE</span><span class="font2"> dan PE isotype control kappa IgG1A was used to study P-gp expression. The procedure was based on the manufacture instruction. Samples were run using FACS Calibur. P-gp positivity was determined based on the percentage (%) of cells stained. Ten percent (10%) of P-gp expression was considered as P-gp overexpression [5]-[7].</span></p>
<ul style="list-style:none;"><li>
<h2><a name="bookmark6"></a><span class="font2"><a name="bookmark7"></a>III. &nbsp;&nbsp;&nbsp;&nbsp;</span><span class="font2" style="font-variant:small-caps;">Results and discussion</span></h2></li></ul>
<p><span class="font2">Eleven samples were able to be studied. Only limited samples were collected because of limited patients, cell viability, and availability of reagents. Based on Mudita (2007), the total ALL cases on children at Sanglah Hospital were 51 cases on the period of 2000-2005 [8].</span></p>
<p><span class="font2">On this study, all the subjects had P-gp overexpression with the range of 56 – 97% (Table I and Figure 1).</span></p>
<p><span class="font0">TABLE I</span></p>
<p><span class="font2" style="font-variant:small-caps;">P-</span><span class="font0" style="font-variant:small-caps;">gp </span><span class="font2" style="font-variant:small-caps;">E</span><span class="font0" style="font-variant:small-caps;">xpression on </span><span class="font2" style="font-variant:small-caps;">P</span><span class="font0" style="font-variant:small-caps;">atients with</span><span class="font0"> ALL</span></p>
<table border="1">
<tr><td rowspan="2" style="vertical-align:middle;">
<p><span class="font0">Subject</span></p></td><td style="vertical-align:middle;">
<p><span class="font0">Number of Cell Stained</span></p></td><td style="vertical-align:middle;">
<p><span class="font0">Cell Total</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">% P-gp positivity (A/B)x 100%</span></p></td><td rowspan="2" style="vertical-align:top;">
<p><span class="font0">P-gp overexpression <sup>a </sup>+ / -</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font0" style="font-style:italic;">A</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0" style="font-style:italic;">B</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0" style="font-style:italic;">C</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font0">1</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">5298</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">7440</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">71%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">+</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font0">2</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">7683</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">9327</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">82%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">+</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font0">3</span></p></td><td style="vertical-align:top;">
<p><span class="font0">5147</span></p></td><td style="vertical-align:top;">
<p><span class="font0">9147</span></p></td><td style="vertical-align:top;">
<p><span class="font0">56%</span></p></td><td style="vertical-align:top;">
<p><span class="font0">+</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font0">4</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">3303</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">4032</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">82%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">+</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font0">5</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">3304</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">3899</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">56%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">+</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font0">6</span></p></td><td style="vertical-align:top;">
<p><span class="font0">7210</span></p></td><td style="vertical-align:top;">
<p><span class="font0">7383</span></p></td><td style="vertical-align:top;">
<p><span class="font0">97%</span></p></td><td style="vertical-align:top;">
<p><span class="font0">+</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font0">7</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">8368</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">8589</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">97%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">+</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font0">8</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">4233</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">6168</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">68%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">+</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font0">9</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">3550</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">6228</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">57%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font0">+</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font0">10</span></p></td><td style="vertical-align:top;">
<p><span class="font0">4372</span></p></td><td style="vertical-align:top;">
<p><span class="font0">5989</span></p></td><td style="vertical-align:top;">
<p><span class="font0">73%</span></p></td><td style="vertical-align:top;">
<p><span class="font0">+</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font0">11</span></p></td><td style="vertical-align:top;">
<p><span class="font0">5105</span></p></td><td style="vertical-align:top;">
<p><span class="font0">6006</span></p></td><td style="vertical-align:top;">
<p><span class="font0" style="text-decoration:underline;">85%</span></p></td><td style="vertical-align:top;">
<p><span class="font0">+</span></p></td></tr>
</table>
<p><span class="font0"><sup>a</sup>P-gp expression on patients with ALL; (+) = P-gp overexpression; (-) = normal P-gp expression.</span></p><img src="https://jurnal.harianregional.com/media/34823-1.jpg" alt="" style="width:184pt;height:180pt;">
<p><span class="font0">Fig. 1. Example of Flow Cytometry Results on Patients number 1</span></p>
<p><span class="font0">(</span><span class="font0" style="font-style:italic;">A)</span><span class="font0"> Cell stained with Isotype Control,</span></p>
<p><span class="font0">(B) P-gp positive Cells (Upper Right and Lower Right Quadrant)</span></p>
<p><span class="font2">On all 11 patients (Table 1 and Figure 1) had P-gp overexpression. P-gp is the member of ATP-binding cassette (ABC) transporter family</span><span class="font2" style="font-style:italic;">.</span><span class="font2"> Hydrophobic medicines (such as vincristine, vinblastine, doxorubicin, and daunorubicin) entry across plasma membrane by diffusion. The activation of energy dependent transport systems can keep the medicines out of cells. It may reduce the drug accumulation on cancer cells [3], [9].</span></p>
<p><span class="font2">On this study, the P-gp expression on all 11 samples were on the range of 56-97% (Table 1). Genetic variation</span></p>
<p><span class="font2">on Multi Drug Resistance-1 (MDR-1) gene, which encoded P-gp, was considered as one of the factors that alter P-gp function and expression [10]-[14]. Many studies in pharmacogenetics and pharmacogenomics showed that variation on </span><span class="font2" style="font-style:italic;">Single Nucleotide Polymorphisms</span><span class="font2"> (SNP) of MDR-1 gene may affect the function and expression of Pgp in different ethnic-populations [2], [15]-[17]. There were 28 exon in MDR-1 gene. Based on the data from </span><span class="font2" style="font-style:italic;">National Center for Biotechnology Information (NCBI)</span><span class="font2">, more than 50 SNPs from MDR-1 gene were found in human. High frequency of variant 3435, 2677, and 1236 MDR-1 Gene were found in Chinese, Malays, Iran, and India [3], [9], [18]-[21]. Haplotype may affect the secondary structure of mRNA and its activity. It will influence the efflux transporter activity and the drug therapeutic response [11], [22]. The difference on haplotype and phenotype can make alteration on </span><span class="font2" style="font-style:italic;">mRNA level,</span><span class="font2"> protein expression, </span><span class="font2" style="font-style:italic;">protein folding</span><span class="font2">, and a </span><span class="font2" style="font-style:italic;">substrate specificity</span><span class="font2"> [3], [11], [23].</span></p>
<p><span class="font2">Variation on MDR-1 gene may influence on diseases progression and therapeutic outcome [3], [24]. In AML, addition of P-gp inhibitor on chemotherapy regimen can increase the probability of remission and survival rate [9], [25]. Mutation on MDR-1 gene may influence the P-gp inhibitor activity. The mutation on haplotype MDR-1 gene may alter the </span><span class="font2" style="font-style:italic;">substrate binding site</span><span class="font2"> [3]. Therefore, further research need to be conducted to identify MDR-1 Gene variation and its association with the P-gp expression level and function in children with ALL in Bali.</span></p>
<ul style="list-style:none;"><li>
<h2><a name="bookmark8"></a><span class="font2"><a name="bookmark9"></a>IV.</span><span class="font2" style="font-variant:small-caps;"> &nbsp;&nbsp;&nbsp;Conclusion</span></h2></li></ul>
<p><span class="font2">P-gp overexpression was detected on all 11 patients in this study. Further research need to be conducted to identify polymorphisms on MDR – 1 Gen MDR-1 and its impact on P-gp expression level and function</span></p>
<h2><a name="bookmark10"></a><span class="font2" style="font-variant:small-caps;"><a name="bookmark11"></a>References</span></h2>
<ul style="list-style:none;"><li>
<p><span class="font0">[1] &nbsp;&nbsp;&nbsp;L. M. Hodges, S. M. Markova, L. W. Chinn, J. M. Gow, D. L. Kroetz, T. E. Klein, and R. B. Altman. (2011, March). Very important pharmacogene summary: </span><span class="font0" style="font-style:italic;">ABCB1</span><span class="font0"> (</span><span class="font0" style="font-style:italic;">MDR1</span><span class="font0">, Pglycoprotein). </span><span class="font0" style="font-style:italic;">Pharmacogenet Genomics</span><span class="font0">. [Online]. </span><span class="font0" style="font-style:italic;">21(3).</span><span class="font0"> pp. 152–161. Available: </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/20216335"><span class="font0">https://www.ncbi.nlm.nih.gov/pubmed/20216335</span></a></p></li>
<li>
<p><span class="font0">[2] &nbsp;&nbsp;&nbsp;L. Yan-Hong, W. Yong-Hua, L. Yan, Y. Ling. (2006, February). MDR1 Gene Polymorphisms and Clinical Relevance. </span><span class="font0" style="font-style:italic;">Acta Genetica Sinica</span><span class="font0">. [Online]. </span><span class="font0" style="font-style:italic;">33 &nbsp;&nbsp;&nbsp;(2).</span><span class="font0"> pp. 93–104. Available:</span></p></li></ul>
<p><a href="http://www.sciencedirect.com"><span class="font0">http://www.sciencedirect.com</span></a><span class="font0"> /science/article/pii/S0379417206600279?via%3Dihub</span></p>
<ul style="list-style:none;"><li>
<p><span class="font0">[3] &nbsp;&nbsp;&nbsp;K. L. Fung and M.M. Gotte. (2009, May). A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. </span><span class="font0" style="font-style:italic;">Biochim Biophys Acta.</span><span class="font0"> [Online]. </span><span class="font0" style="font-style:italic;">1794(5).</span><span class="font0"> pp. 860– 871. Available: </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/19285158"><span class="font0">https://www.ncbi.nlm.nih.gov/pubmed/19285158</span></a></p></li>
<li>
<p><span class="font0">[4] &nbsp;&nbsp;&nbsp;H.J. Broxterman. 1996. How to Probe Clinical Tumour Samples for P-glycoprotein and Multidrug Resistance-associated Protein. </span><span class="font0" style="font-style:italic;">European Journal of Cancer.</span><span class="font0"> [Online]. </span><span class="font0" style="font-style:italic;">33A(6)</span><span class="font0">. pp. 1024-1033. Available: </span><a href="https://www.ncbi.nlm.nih.gov"><span class="font0">https://www.ncbi.nlm.nih.gov</span></a><span class="font0"> /pubmed/8763344</span></p></li>
<li>
<p><span class="font0">[5] &nbsp;&nbsp;&nbsp;A. L. Dogan, A. Kars, H. Canpinar, D. Güç, M. Hayran, W. E. Criss, E. Kansu. (2004). Prediction of Clinical Response to Chemotherapy by </span><span class="font0" style="font-style:italic;">In Vitro</span><span class="font0"> Chemosensitivity Assay In Acute Leukemia. </span><span class="font0" style="font-style:italic;">Turkish Journal of Cancer</span><span class="font0">. [Online]. </span><span class="font0" style="font-style:italic;">34(2).</span><span class="font0"> pp. 75-80. Available: </span><a href="http://www.turkjcancer.org/pdf/pdf_"><span class="font0">http://www.turkjcancer.org/pdf/pdf_</span></a><span class="font0"> TJC_367.pdf</span></p></li>
<li>
<p><span class="font0">[6] &nbsp;&nbsp;&nbsp;V. NÜssler, R. Pelka-Flescher, H. Zwierzina, C. Nerl, B. Beckert, F. Gieseler, H. Diem, Ledderose G, E. Gullis, H. Sauer, W. Wilmanns.</span></p></li></ul>
<p><span class="font0">(1996, July). P-glycoprotein expression in patients with acute leukemia-clinical relevance. </span><span class="font0" style="font-style:italic;">Leukemia</span><span class="font0">. [Online]. </span><span class="font0" style="font-style:italic;">10(Suppl 3).</span><span class="font0"> pp. S23-S31. Available: </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/8656697"><span class="font0">https://www.ncbi.nlm.nih.gov/pubmed/8656697</span></a></p>
<ul style="list-style:none;"><li>
<p><span class="font0">[7] &nbsp;&nbsp;&nbsp;V. NÜssler, R. Pelka-Flescher, H. Zwierzina, C. Nerl, B. Beckert, E. Gullis, F. Gieseler, S. Bock, R. Bartl, P. E. Petrides, </span><span class="font0" style="font-style:italic;">et al</span><span class="font0">. (1994). Clinical Importance of P-glycoprotein-related resistance in Leukemia and Myelodysplastic Syndromes-First Experience with Their Reversal. </span><span class="font0" style="font-style:italic;">Ann. Hematol</span><span class="font0">. [Online]. </span><span class="font0" style="font-style:italic;">69 (Suppl 1).</span><span class="font0"> pp. S25-9. Available: </span><a href="http://link.springer.com/article/10.1007/BF01757351"><span class="font0">http://link.springer.com/article/10.1007/BF01757351</span></a></p></li>
<li>
<p><span class="font0">[8] &nbsp;&nbsp;&nbsp;I B. Mudita. (2007). Pola Penyakit dan Karakteristik Pasien Hemato Onkologi Bagian Ilmu Kesehatan Anak Fakultas Kedokteran Universitas Udayana / Rumah Sakit Sanglah Periode 2000-2005. </span><span class="font0" style="font-style:italic;">Sari Pediatri.</span><span class="font0"> [Online]. </span><span class="font0" style="font-style:italic;">9(1).</span><span class="font0"> pp. 13-16. Available: </span><a href="https://www.researchgate.net/publication/312404291_Pola_Penyakit"><span class="font0">https://www.researchgate.net/publication/312404291_Pola_Penyakit</span></a><span class="font0"> _dan_Karakteristik_Pasien_Hemato_Onkologi_Bagian_Ilmu_Keseha tan_Anak_Fakultas_Kedokteran_Universitas_UdayanaRS_Sanglah_ Denpasar_Periode_2000-2005</span></p></li>
<li>
<p><span class="font0">[9] &nbsp;&nbsp;&nbsp;S. V. Ambudkar, C. Kimchi-Sarfaty, Z. E. Sauna and M. M. Gottesman. (2003). P-glycoprotein: from genomics to mechanism. </span><span class="font0" style="font-style:italic;">Oncogene.</span><span class="font0"> [Online]. </span><span class="font0" style="font-style:italic;">22.</span><span class="font0"> pp. 7468–7485. Available: </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/14576852"><span class="font0">https://www.ncbi.nlm.nih.gov/pubmed/14576852</span></a></p></li>
<li>
<p><span class="font0">[10] &nbsp;&nbsp;&nbsp;J. M. Gow, L. M. Hodges, L. W. Chin, D. L. Kroetz. (2008). Substrate – Dependent Effect of Human ABCB1 Coding Polymorphisms. </span><span class="font0" style="font-style:italic;">J Phamacol Exp Ther</span><span class="font0">. [Online]. 325(2). pp. 435 -442. Available: </span><a href="http://jpet.aspetjournals.org/content/jpet/325/2/435"><span class="font0">http://jpet.aspetjournals.org/content/jpet/325/2/435</span></a><span class="font0">. full.pdf</span></p></li>
<li>
<p><span class="font0">[11] &nbsp;&nbsp;&nbsp;C. Kimchi-Sarfathy, J. M. Oh, I. W. Kim, Z. E. Sauna, A. M. Calcagno. S. V. Ambudkar, M. M. Gottesman. (2007). A Silent Polymorphism in the MDR-1 Gene Changes Substrate Specificity. </span><span class="font0" style="font-style:italic;">Science</span><span class="font0">. &nbsp;&nbsp;&nbsp;[Online]. </span><span class="font0" style="font-style:italic;">315.</span><span class="font0"> pp. 525-528. Available:</span></p></li></ul>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/17185560"><span class="font0">https://www.ncbi.nlm.nih.gov/pubmed/17185560</span></a></p>
<ul style="list-style:none;"><li>
<p><span class="font0">[12] &nbsp;&nbsp;&nbsp;N. N. Salama, Z. Yang, T. Bui, R. J. Ho. (2006). MDR 1 Haplotypes Significantly Minimize Intracellular Uptake and Transcellular P-Gp Substrate Transport in Recombinant LLC-PK1 Cells. </span><span class="font0" style="font-style:italic;">Journal of Pharmaceutical Sciences</span><span class="font0">. [Online]. </span><span class="font0" style="font-style:italic;">95.</span><span class="font0"> pp. 2293 – 2308. Available: </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/16883550"><span class="font0">https://www.ncbi.nlm.nih.gov/pubmed/16883550</span></a></p></li>
<li>
<p><span class="font0">[13] &nbsp;&nbsp;&nbsp;D. L. Kroetz, C. Pauli-Magnus, L. M. Hodges, C. C. Huang, M. Kawamoto, S. J. John, D. Stryke, T. E. Ferrin, J. De Young, T. Taylor, E. J. Carlson, I. Herskowitz, K. M. Giacomini, A. G. Clark. (2003). Sequence Diversity And Haplotype Structure in Human ABCB1 (MDR1, Multi Drug Resistance Transporter) Gene. </span><span class="font0" style="font-style:italic;">Pharmacogenetics</span><span class="font0">. [Online]. </span><span class="font0" style="font-style:italic;">13.</span><span class="font0"> pp. 481-494. Available: </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/16883550"><span class="font0">https://www.ncbi.nlm.nih.gov/pubmed/16883550</span></a></p></li>
<li>
<p><span class="font0">[14] &nbsp;&nbsp;&nbsp;M. K. Leabman, C. C. Huang, J. D. Young, E J. Carlson, T. R. Taylor, D. L. M. Cruz, S. J John, D. Stryke, M. Kawamoto, T. J. Urban, D. L. Kroetz, T. E. Ferrin, A. G. Clark, N. Risch, I. Herskowitz, K. M. Giacomini. (2003). Natural Variation In Human Membrane Transpoter Genes Reveals Evolutionary and Functional Constrains. </span><span class="font0" style="font-style:italic;">Proc Natl Acad Sci USA.</span><span class="font0"> [Online]. </span><span class="font0" style="font-style:italic;">100.</span><span class="font0"> pp. 5896 – 5901. Available: </span><a href="http://www.pnas.org/content/100/10/5896.full.pdf"><span class="font0">http://www.pnas.org/content/100/10/5896.full.pdf</span></a></p></li>
<li>
<p><span class="font0">[15] &nbsp;&nbsp;&nbsp;S. Hoffmeyer, O. Burk, O Richter, H. P. Arnold, J. Brockmoller, A. Johne, I. Cascorbi, T. Gerloff, I. Roots, M. Eichelbaum, U. Brinkmann. (2000). Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity </span><span class="font0" style="font-style:italic;">in vivo</span><span class="font0">. </span><span class="font0" style="font-style:italic;">Proc NatlAcad Sci USA</span><span class="font0">. [Online]. </span><span class="font0" style="font-style:italic;">97</span><span class="font0">. pp. 3473-3478. Available: </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/10716719"><span class="font0">https://www.ncbi.nlm.nih.gov/pubmed/10716719</span></a></p></li>
<li>
<p><span class="font0">[16] &nbsp;&nbsp;&nbsp;R. B. Kim, B. F. Leake, E. F. Choo, G. K. Dresser, S. V. Kubba, U. I. Schwarz, A. Taylor, H. G. Xie, J. McKinsey, S. Zhou, L. B. Lan, J. D. Schuetz, E. G. Schuetz, G. R. Wilkinson. (2001). Identification of functionally variant </span><span class="font0" style="font-style:italic;">MDR</span><span class="font0">1 alleles among European Americans and African Americans. </span><span class="font0" style="font-style:italic;">Clin Pharmacol Ther.</span><span class="font0"> [Online]. </span><span class="font0" style="font-style:italic;">70</span><span class="font0">. pp. 189-199. Available: </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/11503014"><span class="font0">https://www.ncbi.nlm.nih.gov/pubmed/11503014</span></a></p></li>
<li>
<p><span class="font0">[17] &nbsp;&nbsp;&nbsp;M. M. Ameyaw, F. Regateiro, T. Li, X. Liu, M. Tariq, A. Mobarek, N. Thornton, G. O. Folayan, J. Githang’a, A. Indalo, D. Ofori-Adjei, D. A. Price-Evans, H. L. McLeod. (2001). MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. </span><span class="font0" style="font-style:italic;">Pharmacogenetics.</span><span class="font0"> [Online]. </span><span class="font0" style="font-style:italic;">11.</span><span class="font0"> pp. 217221. Available: </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/11337937"><span class="font0">https://www.ncbi.nlm.nih.gov/pubmed/11337937</span></a></p></li>
<li>
<p><span class="font0">[18] &nbsp;&nbsp;&nbsp;M. Saidijam, H. Mahjub, N. Shabab, R. Yadegarazari, (2015). Simultaneous Analyisis of Multidrug Resistance 1 (MDR-1) C3435T, G 2677 T/A, and C1236T Genotype in Hamadan City Population, West of Iran. </span><span class="font0" style="font-style:italic;">Iranian Biomedical Journal</span><span class="font0">. [Online]. </span><span class="font0" style="font-style:italic;">19(1)</span><span class="font0">. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pp. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;57-62. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Available:</span></p></li></ul>
<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322234/"><span class="font0">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322234/</span></a></p>
<ul style="list-style:none;"><li>
<p><span class="font0">[19] &nbsp;&nbsp;&nbsp;A. J. Brambilla-Tapia. (2013). MDR 1 (ABCB1) polymorphisms: functional effects and Clininal Implications. </span><span class="font0" style="font-style:italic;">Revista de Investigacon Clinica.</span><span class="font0"> [Online]. </span><span class="font0" style="font-style:italic;">65(5).</span><span class="font0"> pp. 445 &nbsp;&nbsp;&nbsp;–454. Available:</span></p></li></ul>
<p><a href="https://www.ncbi.nlm.nih"><span class="font0">https://www.ncbi.nlm.nih</span></a><span class="font0">. gov/pubmed/24687344</span></p>
<ul style="list-style:none;"><li>
<p><span class="font0">[20] &nbsp;&nbsp;&nbsp;K. Tang, S. M. Ngoi, P. C. Gwee, J. M. Chua, E. J. Lee, S. S. Chong and C. G. Lee. (2002). Distinct Haplotype Profiles And Strong Linkage Disequilibrium At The MDR1 Multidrug Transporter Gene Locus In Three Ethnic Asian Populations. </span><span class="font0" style="font-style:italic;">Pharmacogenetics</span><span class="font0">. [Online]. </span><span class="font0" style="font-style:italic;">12.</span><span class="font0"> pp. 437–450. Available:https://www.ncbi.nlm.nih.gov/ pubmed/12172212</span></p></li>
<li>
<p><span class="font0">[21] &nbsp;&nbsp;&nbsp;C. J. Chen, D. Clark, K. Ueda, I. Pastan, M. M. Gottesman and I. B. Roninson. (1990, January). Genomic Organization of Human Multidrug Resistance (MDR1) Gene and Origin of P-Glycoprotein. </span><span class="font0" style="font-style:italic;">J Biol Chem.</span><span class="font0"> [Online]. </span><span class="font0" style="font-style:italic;">265(1).</span><span class="font0"> pp. 506-514. Available: </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/1967175"><span class="font0">https://www.ncbi.nlm.nih.gov/pubmed/1967175</span></a></p></li>
<li>
<p><span class="font0">[22] &nbsp;&nbsp;&nbsp;D. Vivona, L. T. Lima, A. C. Rodrigues, C. T. Bueno, G. K. S. Alcantara, L. S. R. Barbos, V. T. D. M. Hungria, C. S. Chiattone, M. D. L. L. D. Chauffaille, E. M. Guerra-Shinohara. (2014). ABCB1 Haplotype are Associated with P-gp Activity and Affect a Major Molecular Response in Chronic Myeloid Leukemia Patients Treated with A standard Dose of Imatinib. </span><span class="font0" style="font-style:italic;">Oncology Letters.</span><span class="font0"> [Online]. </span><span class="font0" style="font-style:italic;">7.</span><span class="font0"> pp. 1313-1319. Available: </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/24660"><span class="font0">https://www.ncbi.nlm.nih.gov/pubmed/24660</span></a><span class="font0"> 038</span></p></li>
<li>
<p><span class="font0">[23] &nbsp;&nbsp;&nbsp;K. L. Fung and M. M. Gottesman. (1794). A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. </span><span class="font0" style="font-style:italic;">Biochim Biophys Acta</span><span class="font0">. </span><span class="font0" style="font-style:italic;">1794</span><span class="font0">. pp. 860-871.</span></p></li>
<li>
<p><span class="font0">[24] &nbsp;&nbsp;&nbsp;A. Ashariati, (2008, October). Polymorphism C3435T of The MDR-1 Gene Predict Response to Preoperative Chemotherapy in Locally Advanced Breast Cancer with Her 2/ neu Expression. </span><span class="font0" style="font-style:italic;">Acta med Indones</span><span class="font0">, [Online]. </span><span class="font0" style="font-style:italic;">40(4).</span><span class="font0"> pp. 187-91. Available: </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/19151448"><span class="font0">https://www.ncbi.nlm.nih.gov/pubmed/19151448</span></a></p></li>
<li>
<p><span class="font0">[25] &nbsp;&nbsp;&nbsp;A. F. List, K. J. Kopecky, C. L. Willman, D. R. Head, D. L. Persons, M. L. Slovak, R. Dorr, C. Karanes, H. E. Hynes, J. H. Doroshow, M. Shurafa and F. R. Appelbaum. (2001). Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. </span><span class="font0" style="font-style:italic;">Blood</span><span class="font0">, [Online]. </span><span class="font0" style="font-style:italic;">98.</span><span class="font0"> pp. 3212–3220. Available: </span><a href="https://www.ncbi.nlm.nih.gov/pubmed"><span class="font0">https://www.ncbi.nlm.nih.gov/pubmed</span></a><span class="font0"> ?cmd=Link &amp;dbFrom =PubMed&amp;from_uid=8874180</span></p></li></ul>